SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

11 Feb 2025 Evaluate
A decent increase of about 29.21% in the sales to Rs. 3118.65 millions was observed for the quarter ended December 2024. The sales figure stood at Rs. 2413.64 millions during the year-ago period.The Total revenue for the quarter ended December 2024 of  Rs. 554.63  millions  grew by 119.33% from Rs. 252.87 millions.OP of the company witnessed a marginal growth to 824.48 millions from 433.00 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 3118.65 2413.64 29.21 8750.17 6280.78 39.32 8532.73 6552.04 30.23
Other Income 225.08 13.25 1598.72 620.17 498.79 24.33 620.73 604.82 2.63
PBIDT 824.48 433.00 90.41 2154.95 1559.11 38.22 2020.08 1523.85 32.56
Interest 3.04 2.67 13.86 8.63 7.60 13.55 9.88 36.13 -72.65
PBDT 821.44 430.33 90.89 2146.32 1551.51 38.34 2010.20 1487.72 35.12
Depreciation 74.22 84.34 -12.00 212.74 216.56 -1.76 291.28 167.37 74.03
PBT 747.22 345.99 115.97 1933.58 1334.95 44.84 1718.92 1320.35 30.19
TAX 192.59 93.12 106.82 426.76 327.28 30.40 381.34 291.69 30.73
Deferred Tax 16.42 -4.44 -469.82 20.90 37.86 -44.80 6.78 -1.71 -496.49
PAT 554.63 252.87 119.33 1506.82 1007.67 49.54 1337.58 1028.66 30.03
Equity 453.16 453.16 0.00 453.16 453.16 0.00 453.16 45316.00 -99.00
PBIDTM(%) 26.44 17.94 47.37 24.63 24.82 -0.79 23.67 23.26 1.79

Marksans Pharma Share Price

197.90 -5.25 (-2.58%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×